Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug

CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study

Fineline Cube May 23, 2025

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...

Company Deals

Viz.ai Partners with Sanofi and Regeneron to Deploy AI Solution for COPD

Fineline Cube May 23, 2025

US-based Viz.ai this week announced a multi-year partnership with France-based Sanofi (NASDAQ: SNY) and US-based...

Company Drug

GSK’s Nucala Receives FDA Approval for COPD Treatment

Fineline Cube May 23, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Drug

Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment

Fineline Cube May 23, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the commercial launch of its hypoxia-inducible...

Company Drug

NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment

Fineline Cube May 23, 2025

China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...

Company Drug

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025

Fineline Cube May 23, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...

Company Deals

Meinian Onehealth Partners with Alibaba DAMO Academy for AI-Driven Disease Screening

Fineline Cube May 23, 2025

China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...

Company Deals

Lead Healthcare Raises RMB 100M in Angel Financing to Boost AI-Driven Life Science Instruments

Fineline Cube May 23, 2025

China-based Lead Healthcare Technology (Guangzhou) Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Deals

WinHealth Pharma Expands Long-Term Partnership with Merz Therapeutics

Fineline Cube May 23, 2025

China-based Hong Kong WinHealth Pharma Group this week formally entered into a long-term partnership with...

Company Deals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

Fineline Cube May 23, 2025

French pharmaceutical firm Servier announced a definitive agreement to acquire BN104 from BioNova Pharmaceuticals (Shanghai)...

Company Drug

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC

Fineline Cube May 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc...

Company Drug Policy / Regulatory

UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt

Fineline Cube May 23, 2025

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification resuming the procurement of UCB’s...

Company Deals

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion

Fineline Cube May 23, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares...

Company Drug

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Fineline Cube May 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US...

Company Drug

Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC

Fineline Cube May 23, 2025

China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...

Company

AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas

Fineline Cube May 23, 2025

AstraZeneca (AZ; NASDAQ: AZN) confirmed the closure of its neuroscience research group during its 2025...

Company Drug

Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes

Fineline Cube May 23, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...

Company Drug

Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy

Fineline Cube May 23, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...

Company Deals

Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M

Fineline Cube May 23, 2025

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81%...

Company Drug

Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA

Fineline Cube May 23, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) recently announced that its New Drug...

Posts pagination

1 … 91 92 93 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.